Company intelligence / Profile preview

Ziarco Pharma

Sandwich, United Kingdom

Ownership: Private
Development stage: Other

Overview

Lead asset ZPL-389 (ZPL389), an oral H4 receptor antagonist, demonstrated 50% reduction in EASI score vs 27% placebo (p=0.01) after 8 weeks in Phase 2 proof-of-concept for atopic dermatitis, with favorable safety profile.[3]

Therapeutic areas: NeurologyImmunologyPulmonologyDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Pfizer Inc.

Beyond the preview

Go deeper on Ziarco Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ziarco Pharma.

Explore the full profile